Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esab (ESAB) Liabilities and Shareholders Equity (2021 - 2025)

Esab (ESAB) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $4.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 18.15% to $4.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 billion, a 14.91% increase, with the full-year FY2025 number at $4.8 billion, up 18.15% from a year prior.
  • Liabilities and Shareholders Equity was $4.8 billion for Q4 2025 at Esab, down from $4.9 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.9 billion in Q4 2025 to a low of $3.5 billion in Q4 2021.
  • A 5-year average of $4.0 billion and a median of $3.8 billion in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 0.56% in 2024, then increased 19.22% in 2025.
  • Esab's Liabilities and Shareholders Equity stood at $3.5 billion in 2021, then increased by 8.46% to $3.8 billion in 2022, then grew by 1.99% to $3.8 billion in 2023, then increased by 5.36% to $4.0 billion in 2024, then rose by 18.15% to $4.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ESAB's Liabilities and Shareholders Equity are $4.8 billion (Q4 2025), $4.9 billion (Q4 2025), and $4.4 billion (Q3 2025).